GLP-1 agonists reduce appetite and food intake across the board
Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP
The patent for semaglutide, a type of GLP-1 drug, is expiring in several countries, including Canada
Stay connected to your care team : Consistent monitoring, guidance and supportbe it from your primary care doctor or even a telehealth provideris the best way to stay on track, identify any issues quickly, and course correct as needed
You may experience a gap between how you see yourself and how your body looks, grief or confusion around identity, or even disappointment if the changes don't meet your expectations
GLP-1 type medications mimic a natural hormone called GLP-1 (glucagon-like peptide-1) which regulates appetite and food intake